<DOC>
	<DOCNO>NCT01037179</DOCNO>
	<brief_summary>The objective study assess safety efficacy long-term use AL-4943A ( Olopatadine Hydrochloride Ophthalmic Solution , 0.2 % ) patient allergic conjunctivitis .</brief_summary>
	<brief_title>An Open-Label , Long-Term Study With AL-4943A Ophthalmic Solution , 0.2 % Patients With Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Subjects must provide write consent . Subjects must diagnosis allergic conjunctivitis . Other protocoldefined inclusion criterion may apply . Itching and/or hyperemia associate diseases allergic conjunctivitis . Retinal detachment , diabetic retinopathy , progressive disease posterior segment eye . Known history ocular infection . Contact lens wear study . Pregnant , nursing . Participation another clinical study within 30 day Informed Consent . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>